✦ LIBER ✦
Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-α-2b : Results of a randomized phase II trial of low-dose versus intermediate-dose interferon-α-2b in patients with metastatic renal cell carcinoma
✍ Scribed by Nizar M. Tannir; Lorenzo Cohen; Xuemei Wang; Peter Thall; Paul F. Mathew; Eric Jonasch; Arlene Siefker-Radtke; Lance C. Pagliaro; Chaan S. Ng; Christopher Logothetis
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 132 KB
- Volume
- 107
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.